Effective October 1, 2024, Medicaid will:

  1. Continue to monitor the stimulant shortage affecting ADHD medications.
  2. Add the Asthma and Allergy Monoclonal Antibodies class to the PDL.
  3. Require PA for generic bepotastine besilate ophthalmic solution, and generic budesonide/formoterol fumarate inhalation, including Breyna. Brand Bepreve and brand Symbicort will remain preferred and will be billed with a Dispense as Written (DAW) Code of 9.
  4. Update the PDL to reflect the quarterly updates listed at the link.

Also in Alabama, this ALERT was published on July 2, 2024; however, Medicaid sent the information to providers again as a reminder of upcoming changes starting on October 1, 2024, related to COVID-19 unwinding.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.